{"filing":{"accession_number":"0001193125-26-336700","cik":"0001789972","ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"cgem-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-20260806.htm"},"events":[{"id":25544,"run_id":23184,"accession_number":"0001193125-26-336700","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Cullinan Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing explicitly states \"announced its financial results for the three and six months ended June 30, 2026\" with a press release furnished as Exhibit 99.1. The exhibit contains consolidated statements of operations showing net loss of $53.7 million for Q2 2026 and $103.4 million for the six-month period, along with balance sheet data and detailed operating expense breakdowns. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26405,"accession_number":"0001193125-26-336700","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Cullinan Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing explicitly states \"announced its financial results for the three and six months ended June 30, 2026\" with a press release furnished as Exhibit 99.1. The exhibit contains consolidated statements of operations showing net loss of $53.7 million for Q2 2026 and $103.4 million for the six-month period, along with balance sheet data and detailed operating expense breakdowns. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:53:34.440316+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26405,"accession_number":"0001193125-26-336700","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Cullinan Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing explicitly states \"announced its financial results for the three and six months ended June 30, 2026\" with a press release furnished as Exhibit 99.1. The exhibit contains consolidated statements of operations showing net loss of $53.7 million for Q2 2026 and $103.4 million for the six-month period, along with balance sheet data and detailed operating expense breakdowns. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:53:34.440316+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-08-06"}]}